| answer text |
<p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’
in the United Kingdom. These are being conducted by two commercial sponsors, Millennium
Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial
sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors
are required to publish a summary of their trial results to the EU Clinical Trials
Register within one year of their trial completing. At that point, these results will
become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p>
</p><p>The Department of Health, which funds the National Institute for Health Research
(NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical
Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay
representatives to coordinate development of a strategic portfolio of trials within
their field. All CSGs interact with clinical research networks, funders (including
NIHR) and researchers to develop studies aimed at improving outcomes for patients.
The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report
that includes an assessment of progress in these areas is attached and available on
the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf"
target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p>
</p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results
are known, the commercial potential of these trial’s products will be a matter for
the respective trial sponsors.</p><p> </p>
|
|
